Navigation Links
OncoSec Doses First Patient in Phase II Clinical Trial for Metastatic Melanoma
Date:2/28/2012

SAN DIEGO, Feb. 28, 2012 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that Investigational Review Board (IRB) approval has been received by the University of California San Francisco and the first patient has been dosed for a Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of advanced stage cutaneous and in-transit metastatic melanoma. UCSF investigators are actively recruiting for this clinical trial.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

"Results from our open-label Phase I study demonstrated that DNA IL-12 and electroporation has the potential to establish a new standard of care for the treatment of late-stage metastatic melanoma," said Punit Dhillon, President and CEO of OncoSec. "With immune response results from this Phase II study expected in the second half of 2012, we are confident this study will validate the value of OMS ElectoImmunotherapy."

A total of up to 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma will be enrolled in this Phase II, single-arm, open-label and multi-center study. The trial is designed to assess local and distant objective response following treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation with a primary endpoint of 24 weeks. One treatment cycle will consist of three treatments applied to up to four lesions on days 1, 5 and 8 with a maximum dose of 1.5 mg DNA IL-12 per treatment cycle. At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety.

OMS ElectroImmunotherapy utilizes OncoSec's proprietary
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoSec to Present at World Cancer Immunotherapy Conference
2. OncoSec to Present at the 22nd Annual Oppenheimer Healthcare Conference
3. OncoSec to Present at 15th Annual Biotech and Specialty Pharmaceuticals Conference
4. OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
5. OncoSec to Present at Medical Device Investor Forum
6. Device Master File for OncoSec Medical System Completed and Submitted to FDA
7. OncoSec Releases Devices for Use in Clinical Trials
8. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
9. OncoSec Announces Positive Results from Head & Neck and Breast Cancer Trials
10. OncoSec Medical to Attend 6th Annual Fire, Ice and Beyond: The Future of Ablation Therapies Conference
11. OncoSec Medical to Present at Industry and Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... BERGEN, Norway , September 23, 2014 /PRNewswire/ ... "Company"), an oncology biopharmaceutical company, today announces it ... million) Seeding Drug Discovery Award from the UK,s ... against BGB002, its proprietary, novel cancer target. ... are to identify and fund especially promising, innovative ...
(Date:9/23/2014)... , Sept. 23, 2014  As physicians ... to digital communication channels to learn about new ... finding – from a new report by global ... – shows that communicating via a customized mix ... provides the best opportunity to engage with physicians. ...
(Date:9/23/2014)... , Sept. 23, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... additions to its Scientific Advisory Board.  The new members ... Davies , PhD. Dr. Acker is a ...
Breaking Medicine Technology:BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 2BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7
... SAN ANTONIO, Feb. 28, 2011 Advanced Cell ... its clinical study utilizing RNAscope™ technology to detect ... specimens of head and neck cancer. HPV status ... predictive of patient outcome and highly concordant with ...
... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... chief executive officer, is scheduled to present a company ... March.  Details of each conference are as follows:Citi Global ... ETLocation:  New York, NY Cowen and Company 31st Annual ...
Cached Medicine Technology:ACD Announces Clinical Study Results Using its RNAscope™ Technology 2ACD Announces Clinical Study Results Using its RNAscope™ Technology 3Rigel to Present at Three Upcoming Investor Conferences 2
(Date:9/23/2014)... Wellesley, Mass., September 23, 2014 – ... report, Joint Reconstruction and Replacement: Materials, Technologies, ... reconstruction and replacement is expected to increase to nearly ... rate (CAGR) of 4.2% from 2013 through 2018. The ... surging at a CAGR of 5.1%. , Revision and ...
(Date:9/23/2014)... 23, 2014 The print component of ... Metro, with a circulation of approximately 327,720 copies and ... distributed nationally through a vast social media strategy and ... outlets. To explore the digital version of the campaign, ... exclusive interview with Michael Landsberg, host of TSN’s Off ...
(Date:9/23/2014)... awarded $10.1 million in supplemental funding to bolster the ... sex in preclinical and clinical studies. , This investment ... a catalyst for considering sex as a fundamental variable ... preclinical research can obscure key findings related to sex ... will result in greater awareness of the need to ...
(Date:9/23/2014)... September 23, 2014 With summer at ... in spirit and weather), organic food manufacturing company Earth ... month centered on sweet treats for the whole family. ... bite-sized candies by the handful in celebration of the ... recent years these festivities come with an increasing degree ...
(Date:9/23/2014)... 2014 The U.S. Pharmacopeial Convention (USP) ... Health Organization (WHO) regarding the assignment of Biological Qualifiers ... by the Expert Group of the Programme of International ... to the naming of all biologicals that is consistent ... assessment of these drugs. , Hence, USP supports ...
Breaking Medicine News(10 mins):Health News:Global Market for Joint Reconstruction and Replacement to reach $16.2 Billion in 2018; The U.S. Market Moving at 5.1% CAGR 2Health News:Global Market for Joint Reconstruction and Replacement to reach $16.2 Billion in 2018; The U.S. Market Moving at 5.1% CAGR 3Health News:‘Sick, not weak’: Mediaplanet’s "Mental Health” Campaign Dispels Stigmas and Bolsters Support for the One in Five Canadians Suffering Mental Illness 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 3Health News:Righteously Raw Chocolates Promote Healthy, Fun Snacking this Fall Season 2Health News:USP Comments to WHO Regarding Biologics Qualifier Proposal 2
... organizations that address health care ... access and priorities in a four-state region, PORTLAND, ... insurer in the Northwest/ Intermountain region, announced today the,launch ... in,the United States. The Regence Foundation estimates it will ...
... Northwest Hospital &,Medical Center announced today that it will ... 2008 KING 5 Healthy Living Expo, from 10 a.m.,- ... 20, at the Qwest Field,Exhibition Center West Hall., ... expected attendance,of more than 44,000 people. Admission is free., ...
... April 14 U.S. Environmental,Protection Agency Region 5 ... alleged clean-air violations at the company,s coal preparation,plant ... Beallsville, Ohio., The agreement, which includes a ... comply with testing, notification and,reporting requirements at the ...
... can cause an aggressive,form of acute lymphoblastic leukemia ... April 14 Researchers at St.,Jude Children,s Research ... mutations work together to initiate most cases of ... (ALL)., These defects, known as "cooperating oncogenic ...
... CCA Industries, Inc.,(Amex: CAW ) announced today ... share fully diluted of $0.05 for the first,quarter ended ... year,were $13,975,385, and net income was $472,753, with fully ... net income has always been the lowest quarter,because the ...
... petinsurance.com, BREA, Calif., April 14 Veterinary ... of pet health insurance, has,designated the last Sunday ... as National,Pet Parent,s Day, slating the nation,s first ... of a spring season set aside for,celebrating parents ...
Cached Medicine News:Health News:Newly Launched Regence Foundation to Help Transform Health Care and Influence the Nationwide Health Care Debate 2Health News:Northwest Hospital & Medical Center Hosts Health & Wellness Pavilion At Second Annual King 5 Healthy Living Expo 2Health News:St. Jude Discovery Offers New Avenues to Understanding an Aggressive Form of Leukemia 2Health News:St. Jude Discovery Offers New Avenues to Understanding an Aggressive Form of Leukemia 3Health News:CCA Industries, Inc. Announces First Quarter Results 2Health News:Veterinary Pet Insurance Launches National Pet Parent's Day 2
... ORTHOSET Radiopaque Bone Cement ... system: a sterile,ampule containing bone ... pack, and a sterile polyethylene ... a peelable pouch. The interiors ...
Antibiotics (Gentamicin) loaded, low viscosity bone cement for syringe use with an average setting time of approx. 7-9 Min., 41.6g of powder and 16.4g of liquid....
... Featuring new technology, such as a recessed ... and lens housings, this arthroscope has superior ... by EO, Steris and steam autoclaving or ... Light post/adapters to fit ACMI, Wolf, Dyonics ...
... Passport II delivery device is the second ... C11UB. Its simple-to-use syringe technology allows one-handed ... small incision. The blue colored plunger allows ... protect the haptics during insertion. The modified ...
Medicine Products: